Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review

Caruso, Rosangela; Nanni, Maria Giulia; Riba, Michelle; Sabato, Silvana; Mitchell, Alex J.; Croce, E; Grassi, Luigi

doi:10.1080/0284186x.2016.1266090

Cited by 147 publications

(115 citation statements)

References 93 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…7 In a recent review, Fervaha et al in 2019, identified that one in six men affected by PCa will experience depression, and that suicidal ideation and death by suicide were higher compared with PCa survivors without depression. [9][10][11][12] These findings have also been corroborated in a recent survey of PCa survivors in Nova Scotia, New Brunswick, and Prince Edward Island, Canada. 5,8 Several relevant contributing factors for mental health have been identified including functional (erectile, urinary and/or bowel dysfunction), psychological (anxiety, stress, depressive symptoms, learned helplessness, lack of cognitive reframing strategies), and social issues (being single, lack of social support or choosing social isolation).…”

Section: Introductionsupporting

confidence: 56%

Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer

2019

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 56%

Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer

2019

View full text Add to dashboard Cite

show abstract

“…Depression is estimated to be two to three times more common among cancer patients than the general population . In colon cancer patients, the prevalence of depression was reported to be 13% to 25% in a systematic review of the literature by Massie .…”

Section: Introductionmentioning

confidence: 99%

Use of antidepressants after colon cancer diagnosis and risk of recurrence

Pocobelli

Ziebell

et al. 2019

Psycho-Oncology

View full text Add to dashboard Cite

Objective Prior research examining the association between use of antidepressants after colon cancer diagnosis and risk of recurrence is scant. We evaluated this association among colon cancer patients diagnosed at two integrated health care delivery systems in the United States. Methods We conducted a cohort study of stage I to IIIA colon cancer patients diagnosed at greater than or equal to 18 years of age at Kaiser Permanente Colorado and Kaiser Permanente Washington during 1995 to 2014. We used pharmacy records to identify dispensings for antidepressants and tumor registry records and patients' medical charts to identify cancer recurrences. Using Cox proportional hazards models, we estimated the adjusted hazard ratio (HR) of colon cancer recurrence comparing patients who used antidepressants after diagnosis to those who did not. We also evaluated the risk associated with use of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) separately. Results Among the 1923 eligible colon cancer patients, 807 (42%) used an antidepressant after diagnosis and 139 had a colon cancer recurrence during an average 5.6 years of follow‐up. Use of antidepressants after colon cancer diagnosis was not associated with risk of recurrence (HR: 1.14; 95% confidence interval [CI], 0.69‐1.87). The HR for use of SSRIs was 1.22 (95% CI, 0.64‐2.30), and for TCAs, it was 1.18 (95% CI, 0.68‐2.07). Conclusions Our findings suggest that use of antidepressants after colon cancer diagnosis was common and not associated with risk of recurrence. Future larger studies with greater power to examine risk associated with individual antidepressants would be valuable additions to the evidence base.

show abstract

“…Depression occurs in up to 60% of people with cancer, with prevalence varying based on cancer type and the extent of the disease . Cancer patients may manifest depression as an ongoing condition, in response to their disease, or as a side effect of treatment, such as the neuropsychiatric effect of chemotherapy .…”

Section: Introductionmentioning

confidence: 99%

Effects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment

et al. 2018

View full text Add to dashboard Cite

Objective This manuscript assesses association between depressive symptoms and symptoms from cancer and its treatment during the first 12 weeks of a new oral oncolytic treatment. Methods This secondary analysis used data from a recently completed trial of an intervention to improve adherence to oral oncolytic treatment and manage symptoms. Following the initiation of the new oral oncolytic medication, 272 patients were interviewed at intake and weeks 4, 8, and 12 to assess depressive symptoms, and symptoms from cancer and its treatment. Depressive symptoms were measured using the Center for Epidemiologic Studies‐Depression (CES‐D20). The summed index of 18 cancer‐related and treatment‐related symptoms as well as the number of symptoms above threshold at intake, weeks 4, 8, and 12 were related to intake and time‐varying CES‐D20 using linear mixed effects models. Results Depressive symptomatology was a significant predictor of cancer‐related and treatment‐related symptoms at all‐time points, but the strength of this relationship was greatest at the time of oral oncolytic agent initiation and at week 4. The strength of this relationship was the same for both summed symptom severity index and the number of symptoms above threshold, and using either intake or time‐varying CES‐D20. Conclusion Introducing strategies to treat and manage symptoms of depression along with other symptoms might have added benefits among patients who start a new oral oncolytic treatment and report modest to higher levels of depressive symptoms. Assessments for the impact of strategies to lower depressive symptoms can be taken within the first 4 weeks.

show abstract

Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review

Abstract: Routine screening and adequate assessment of depressive spectrum disorders is necessary in patients with cancer in order to effectively manage the multifaceted and complex consequences on cancer care.

Cited by 147 publications

References 93 publications

Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer

Anxiety and depression symptoms in adult males in Atlantic Canada with or without a lifetime history of prostate cancer

Use of antidepressants after colon cancer diagnosis and risk of recurrence

Effects of depressive symptomatology on cancer‐related symptoms during oral oncolytic treatment

Contact Info

Product

Resources

About